A phase 2, multi-center, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and efficacy of LymphoStat-B antibody (monoclonal anti-BLyS antibody) in subjects with systemic lupus erythematosus (SLE)

Trial Profile

A phase 2, multi-center, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and efficacy of LymphoStat-B antibody (monoclonal anti-BLyS antibody) in subjects with systemic lupus erythematosus (SLE)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2013

At a glance

  • Drugs Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Biomarker; Therapeutic Use
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 28 May 2011 Pooled tolerability results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 25 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top